Treatment of Sight-Threatening Graves' Orbitopathy with Dysthyroid Optic Neuropathy or Corneal Breakdown
Sight-threatening Graves' orbitopathy — classified as very severe — is an acute orbital emergency. When dysthyroid optic neuropathy or corneal breakdown is present, immediate intervention is required and treatment of the orbital disease takes absolute priority.
Clinical Scenario
This protocol is specific to patients with Graves' orbitopathy presenting at the sight-threatening (very severe) severity grade, defined by the presence of dysthyroid optic neuropathy and/or corneal breakdown. This constitutes an emergency condition in which orbital treatment cannot be deferred.
Treatment Approach
The cornerstone of management is immediate high-dose intravenous corticosteroid therapy, started without delay. Concurrent thyroid status is addressed to support the orbital treatment course. The complete protocol — including the specific schedule, escalation criteria, and sequential steps — is available in full via the link below.
Treatment Goal
Improvement (without deterioration) of visual acuity and visual fields, assessed at one week of therapy. Absence of response within the defined evaluation window triggers a defined next step.
References
DOI: 10.1530/EJE-21-0479
Patients with dysthyroid optic neuropathy and/or corneal breakdown.
Optic neuropathy should be treated immediately with high single doses of i.v. methylprednisolone (0.5–1 g of methylprednisolone daily for either three consecutive days or more preferably on every second day), and urgent orbital decompression should be performed if response is absent or poor within 1–2 weeks.
Sight-threatening GO: in this emergency condition, treatment of GO is an absolute priority; hyperthyroidism should be treated with ATDs until treatment of GO is completed.
When the response is absent or poor with a deterioration in visual acuity or visual fields, urgent orbital decompression surgery is mandatory.
View source ↗